Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

Research output: Contribution to journalArticle

Standard

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. / European Research Initiative on CLL (ERIC); Baliakas, Panagiotis; Moysiadis, Theodoros; Hadzidimitriou, Anastasia; Xochelli, Aliki; Jeromin, Sabine; Agathangelidis, Andreas; Mattsson, Mattias; Sutton, Lesley Ann; Minga, Eva; Scarfò, Lydia; Rossi, Davide; Davis, Zadie; Villamor, Neus; Parker, Helen; Kotaskova, Jana; Stalika, Evangelia; Plevova, Karla; Mansouri, Larry; Cortese, Diego; Navarro, Alba; Delgado, Julio; Larrayoz, Marta; Young, Emma; Anagnostopoulos, Achilles; Smedby, Karin E.; Juliusson, Gunnar; Sheehy, Oonagh; Catherwood, Mark; Strefford, Jonathan C.; Stavroyianni, Niki; Belessi, Chrysoula; Pospisilova, Sarka; Oscier, David; Gaidano, Gianluca; Campo, Elias; Haferlach, Claudia; Ghia, Paolo; Rosenquist, Richard; Stamatopoulos, Kostas.

In: Haematologica, Vol. 104, No. 2, 2019, p. 360-369.

Research output: Contribution to journalArticle

Harvard

European Research Initiative on CLL (ERIC), Baliakas, P, Moysiadis, T, Hadzidimitriou, A, Xochelli, A, Jeromin, S, Agathangelidis, A, Mattsson, M, Sutton, LA, Minga, E, Scarfò, L, Rossi, D, Davis, Z, Villamor, N, Parker, H, Kotaskova, J, Stalika, E, Plevova, K, Mansouri, L, Cortese, D, Navarro, A, Delgado, J, Larrayoz, M, Young, E, Anagnostopoulos, A, Smedby, KE, Juliusson, G, Sheehy, O, Catherwood, M, Strefford, JC, Stavroyianni, N, Belessi, C, Pospisilova, S, Oscier, D, Gaidano, G, Campo, E, Haferlach, C, Ghia, P, Rosenquist, R & Stamatopoulos, K 2019, 'Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia', Haematologica, vol. 104, no. 2, pp. 360-369. https://doi.org/10.3324/haematol.2018.195032

APA

European Research Initiative on CLL (ERIC), Baliakas, P., Moysiadis, T., Hadzidimitriou, A., Xochelli, A., Jeromin, S., ... Stamatopoulos, K. (2019). Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica, 104(2), 360-369. https://doi.org/10.3324/haematol.2018.195032

CBE

European Research Initiative on CLL (ERIC), Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K. 2019. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 104(2):360-369. https://doi.org/10.3324/haematol.2018.195032

MLA

Vancouver

European Research Initiative on CLL (ERIC), Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019;104(2):360-369. https://doi.org/10.3324/haematol.2018.195032

Author

European Research Initiative on CLL (ERIC) ; Baliakas, Panagiotis ; Moysiadis, Theodoros ; Hadzidimitriou, Anastasia ; Xochelli, Aliki ; Jeromin, Sabine ; Agathangelidis, Andreas ; Mattsson, Mattias ; Sutton, Lesley Ann ; Minga, Eva ; Scarfò, Lydia ; Rossi, Davide ; Davis, Zadie ; Villamor, Neus ; Parker, Helen ; Kotaskova, Jana ; Stalika, Evangelia ; Plevova, Karla ; Mansouri, Larry ; Cortese, Diego ; Navarro, Alba ; Delgado, Julio ; Larrayoz, Marta ; Young, Emma ; Anagnostopoulos, Achilles ; Smedby, Karin E. ; Juliusson, Gunnar ; Sheehy, Oonagh ; Catherwood, Mark ; Strefford, Jonathan C. ; Stavroyianni, Niki ; Belessi, Chrysoula ; Pospisilova, Sarka ; Oscier, David ; Gaidano, Gianluca ; Campo, Elias ; Haferlach, Claudia ; Ghia, Paolo ; Rosenquist, Richard ; Stamatopoulos, Kostas. / Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. In: Haematologica. 2019 ; Vol. 104, No. 2. pp. 360-369.

RIS

TY - JOUR

T1 - Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

AU - European Research Initiative on CLL (ERIC)

AU - Baliakas, Panagiotis

AU - Moysiadis, Theodoros

AU - Hadzidimitriou, Anastasia

AU - Xochelli, Aliki

AU - Jeromin, Sabine

AU - Agathangelidis, Andreas

AU - Mattsson, Mattias

AU - Sutton, Lesley Ann

AU - Minga, Eva

AU - Scarfò, Lydia

AU - Rossi, Davide

AU - Davis, Zadie

AU - Villamor, Neus

AU - Parker, Helen

AU - Kotaskova, Jana

AU - Stalika, Evangelia

AU - Plevova, Karla

AU - Mansouri, Larry

AU - Cortese, Diego

AU - Navarro, Alba

AU - Delgado, Julio

AU - Larrayoz, Marta

AU - Young, Emma

AU - Anagnostopoulos, Achilles

AU - Smedby, Karin E.

AU - Juliusson, Gunnar

AU - Sheehy, Oonagh

AU - Catherwood, Mark

AU - Strefford, Jonathan C.

AU - Stavroyianni, Niki

AU - Belessi, Chrysoula

AU - Pospisilova, Sarka

AU - Oscier, David

AU - Gaidano, Gianluca

AU - Campo, Elias

AU - Haferlach, Claudia

AU - Ghia, Paolo

AU - Rosenquist, Richard

AU - Stamatopoulos, Kostas

PY - 2019

Y1 - 2019

N2 - Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or SF3B1 mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.

AB - Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or SF3B1 mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.

U2 - 10.3324/haematol.2018.195032

DO - 10.3324/haematol.2018.195032

M3 - Article

VL - 104

SP - 360

EP - 369

JO - Haematologica-The Hematology Journal

T2 - Haematologica-The Hematology Journal

JF - Haematologica-The Hematology Journal

SN - 1592-8721

IS - 2

ER -